Testosterone Hormone Therapy Guidelines for Transgender Men

Target Serum Testosterone Concentrations

• Maintain total testosterone between 300 – 1,000 ng/dL (the typical cisgender male physiological range), aiming for the mid‑normal range of 450 – 600 ng/dL to balance masculinization efficacy with safety. [1][2]

Rationale for the Target Range

• The 300 – 1,000 ng/dL interval reflects physiological levels observed in cisgender men and is the standard goal for masculinizing therapy. 1
• Targeting the mid‑normal range (450 – 600 ng/dL) reduces the risk of erythrocytosis and cardiovascular complications while providing adequate virilization. 2
• Testosterone levels < 300 ng/dL can impair bone density and limit desired masculinization; levels > 1,000 ng/dL increase adverse effects without added benefit. 1

Timing and Frequency of Testosterone Monitoring

• Injectable formulations (testosterone cypionate or enanthate): draw trough levels immediately before the next scheduled injection. 2
• Initial monitoring 2–3 months after therapy start or any dose change; thereafter every 3–6 months during the first year and every 6–12 months once stable. 2

Expected Physical Changes and Timeline

All timelines are supported by clinical observations in transgender men. [1][2]

Hematologic Monitoring & Erythrocytosis Risk

• Erythrocytosis/polycythemia occurs in ≈ 44 % of transgender men using injectable testosterone. [1][2]
• Transdermal testosterone gel carries a lower erythrocytosis incidence (≈ 15 %) compared with injectables. 2
• Monitor hemoglobin and hematocrit at baseline, at 3 months, then every 6–12 months. 2
• If hematocrit exceeds 54 % (or rises above the male reference range), consider dose reduction, switching to a transdermal formulation, or therapeutic phlebotomy. 2

Cardiovascular and Metabolic Monitoring

• Testosterone therapy may increase blood pressure, triglycerides, and LDL cholesterol while decreasing HDL cholesterol. 1
• Regular lipid panel and blood pressure checks are advised, especially for patients with pre‑existing cardiovascular risk factors. 2
• Large cohort studies have not demonstrated a significant rise in cardiovascular mortality among transgender men on testosterone. 1

Formulation Selection and Dosing Strategies

Injectable Testosterone (most common)

• Dose: 100–200 mg intramuscularly or subcutaneously every 2 weeks, or 50–100 mg weekly. 2
• Weekly dosing provides more stable serum levels and lowers erythrocytosis risk relative to bi‑weekly dosing. 2

Transdermal Testosterone Gel (1.62 %)

• Starting dose: 40.5 mg applied daily to shoulders, upper arms, or abdomen. 2
• Offers stable day‑to‑day levels and reduced erythrocytosis risk, making it preferable for patients with elevated hematocrit or heightened cardiovascular risk. 2

Cost Comparison (annual, generic estimate)

Cost data reflect typical pricing in the United States.

Long‑Acting Testosterone Undecanoate

• Generally avoided because of rare but serious risks of pulmonary oil micro‑embolism and anaphylaxis; use only within risk‑evaluation programs. 1

Common Pitfalls to Avoid

• Supraphysiologic dosing (levels consistently > 1,000 ng/dL) increases adverse effects—particularly erythrocytosis—without additional masculinization benefit. 2
• Measuring peak levels (2–5 days post‑injectable) can misrepresent average exposure and may lead to inappropriate dose reductions; trough levels are preferred. 2
• Mild hematocrit elevations (50–52 %) should trigger closer surveillance and possible dose adjustment, especially in patients with cardiovascular risk factors. 2
• Bone health oversight: Inadequate testosterone dosing can impair bone mineral density; appropriate dosing and monitoring are essential. 1

Quality‑of‑Life and Mental‑Health Benefits

• Testosterone‑based gender‑affirming hormone therapy is medically necessary for many transgender individuals and is associated with significant improvements in quality of life, reduced gender dysphoria, and lower rates of anxiety and depression. [1][2]
• Most desired physical effects appear within 6–12 months, while maximal virilization typically requires 3–5 years of consistent therapy. 1

Hormone Therapy for Female-to-Male Transition

Standard Testosterone Regimen

• The typical hormone therapy regimen for female-to-male transition consists of testosterone therapy with standard dosing aimed at achieving serum testosterone concentrations of 300-1,000 ng/dL, most commonly administered via intramuscular or subcutaneous injection of testosterone cypionate or enanthate, as recommended by the medical community 3, 4, 5

Target Hormone Levels and Monitoring

• Maintain trough testosterone levels between 300-1,000 ng/dL, as recommended by the Endocrine Society 4, 5
• The Endocrine Society recommends targeting the mid-normal range to optimize safety and efficacy 5
• Hemoglobin will increase to the male reference range within 3 months of starting therapy 3

Expected Physical Changes

• Deepening of voice due to thickened vocal cords, as well as facial and body hair growth, are expected physical changes 3
• Menstrual suppression is typically achieved in most patients, and clitoral growth, increased muscle mass and decreased fat mass, and increased libido are also expected 3, 6

Critical Monitoring Parameters

• Monitor for erythrocytosis/polycythemia, which is particularly common with injectable formulations, and consider switching to transdermal route if it develops 4, 5
• Monitor blood pressure, as testosterone may increase blood pressure, and check lipid profiles regularly, as testosterone may increase triglycerides and LDL cholesterol while decreasing HDL 4, 5

Common Pitfalls and Adverse Effects

• Avoid supraphysiologic dosing, which increases risk of adverse effects without additional benefit 5
• Androgenic alopecia and acne are common, and gynecological effects, including pelvic pain and genital dryness, may occur 3
• Reduced HDL cholesterol and potential increased risk of myocardial infarction are also possible adverse effects 3

Testosterone Therapy for Female-to-Male Transition

Pre-Treatment Screening and Monitoring

• The American Association for the Study of Liver Diseases recommends screening for liver abnormalities and obtaining baseline polycythemia assessment before initiating testosterone therapy, as testosterone may cause transient elevations in liver enzymes 7
• The Endocrine Society suggests that patients with advanced liver disease can receive testosterone therapy, though closer monitoring is warranted 7
• According to the Hepatology society, benefits of testosterone therapy in patients with chronic liver disease include increases in muscle and bone mass, with a trend toward lowering mortality 7
• If hematocrit rises above normal male reference range, consider temporarily withholding therapy, reducing dose, or performing phlebotomy, as recommended by the New England Journal of Medicine 8

Testosterone Therapy for Transgender Patients

Introduction to Testosterone Therapy

• The American College of Physicians recommends transdermal testosterone gel (1.62%) as the most effective non-injectable option for transgender patients with needle phobia, with a starting dose of 40.5 mg daily, targeting serum testosterone levels of 300-1,000 ng/dL 9

Physical Effects of Testosterone Therapy

• Transdermal testosterone gel produces masculinizing effects, including voice deepening, facial and body hair growth, and increased muscle mass and strength, with a lower risk of erythrocytosis compared to injectable formulations 9
• Inadequate testosterone dosing can negatively impact bone density, making appropriate dosing and monitoring essential 9

Alternative Testosterone Options

• Testosterone patches (50-100 μg/24 hours) are another transdermal option that may be considered for needle-phobic patients, though specific dosing protocols are less well-defined in the transgender medicine literature 9
• Testosterone undecanoate (long-acting injectable) should be avoided due to concerns for pulmonary oil microembolism and anaphylaxis, and is subject to risk evaluation and mitigation strategies 9

Quality of Life and Mental Health Benefits

• Gender-affirming hormone therapy with testosterone is medically necessary for many transgender individuals, with strong evidence showing improvements in quality of life and relief of psychological distress associated with gender dysphoria 10, 11